BEGIN:VCALENDAR
PRODID:-//Columba Systems Ltd//NONSGML CPNG/SpringViewer/ICal Output/3.3-
 M3//EN
VERSION:2.0
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTAMP:20190523T122953Z
DTSTART:20190604T130000Z
DTEND:20190604T134500Z
SUMMARY:Application of pharmacoepidemiology in ADHD research - Professor 
 Ian Wong\, University of Hong Kong
UID:{http://www.columbasystems.com/customers/uom/gpp/eventid/}a1lb-jw0mvw
 zp-s812xy
DESCRIPTION:'Application of pharmacoepidemiology in ADHD research'\n\nPro
 fessor Ian Wong\, Professor in Pharmacy\, Head of Department of Pharmaco
 logy and Pharmacy\,  The University of Hong Kong is visiting the Univers
 ity of Manchester\, and giving a lecture on\n\nAbstract:\n\nAttention de
 ficit/hyperactivity disorder (ADHD) is one of the most common neurodevel
 opmental disorders of childhood with estimated worldwide prevalence amon
 g school-aged children of 5-7%. Some studies have reported that prenatal
  exposure to antidepressants increases the risk of ADHD in childhood\; h
 owever\, many methodological issues make the interpretation of these stu
 dies’ results difficult.  Our research has shown that in the past two de
 cades\, medications for the treatment of ADHD has risen rapidly globally
  [1]. Safety concerns of these medications\, particularly methylphenidat
 e\, have been raised by general public\, healthcare professionals and re
 gulatory agencies.\n\nIn this seminar\, I will share some of the results
  of my ADHD pharmacoepidemiology research programme in Hong Kong. I will
  specifically discuss the association between prenatal exposure of antid
 epressants and ADHD [2] and also the association of psychiatric adverse 
 events and treatment of methylphenidate [3-5].\n\nReferences:\n\n[1] Ram
 an at al Lancet Psychiatry 2018 Oct 5.\n\n[2] Man et al BMJ. 2017 May 31
 .\n\n[3] Man et al JAMA Psychiatry. 2017 Jul 26.\n\n[4] Man et al Transl
  Psychiatry. 2016 Nov 15\n\n \n\nBiography:          \n\nProfessor Ian W
 ong is an alumnus of University of Manchester [MSc (1996) and PhD (1998)
 ]. He is currently the Head of Department of Pharmacology and Pharmacy\,
  University of Hong Kong. He is also the holder of Lo Shiu Kwan Kan Po L
 ing Endowed Professorship in Pharmacy.\n\nAs an academic pharmacist with
  expertise in pharmacoepidemiology and big data research\, Professor Won
 g has over 250 publications with publication in JAMA\, JAMA Internal Med
 icine\, JAMA Psychiatry\, Lancet Psychiatry\, Lancet Infectious Disease\
 , BMJ.  According to Clarivate Analytics' Essential Science Indicators\,
  Professor Wong has been a top 1% scholar in 2015 to 2018.\n\nProfessor 
 Wong received the Chemist and Druggist's Pharmacy Practice Research Meda
 l in 2004 for his research in paediatric medicines. In recognition of hi
 s work in paediatric medicines research\, Professor Wong was awarded an 
 Honorary Fellowship of the Royal College of Paediatrics and Child Health
  in 2011\, and Fellowship of the Royal Pharmaceutical Society in 2012. H
 e was the coordinator of the ADDUCE consortium which was funded by the E
 uropean Commission to evaluate the long-term safety of methylphenidate. 
 He was a member of the NICE ADHD guideline development group in 2009 and
  2018 respectively.\n\nIn 2006\, Professor Wong set up a UCL spin-off co
 mpany with Great Ormond Street Hospital for Children (Therakind)\, a pae
 diatric healthcare company\, that creates\, develops\, and improves paed
 iatric and other specialty medicinal products. It develops Buccolam®\, a
  treatment for prolonged acute convulsive seizures in children\; Ayendi®
 \, an intranasal paediatric pain control product\; and Jylamvo®\, an ora
 l syrup for juvenile idiopathic arthritis
STATUS:TENTATIVE
TRANSP:TRANSPARENT
CLASS:PUBLIC
LOCATION:Lecture Theatre 4\, Stopford Building\, Manchester
END:VEVENT
END:VCALENDAR